title: MicroRNA-92a Promotes Cell Proliferation in Cervical Cancer via Inhibiting p21 Expression and Promoting Cell Cycle Progression.
abstract: MicroRNA-92a (miR-92a) generally plays a promoting role in human cancers, but the underlying mechanism in cervical cancer remains unclear. Here we studied the expression and clinical significance of miR-92a in cervical cancer, as well as the regulatory mechanism in the proliferation of cervical cancer cells. Our data indicated that miR-92a was significantly upregulated in cervical cancer tissues compared to their matched adjacent nontumor tissues (ANTs), and the increased miR-92a levels were significantly associated with a higher grade, lymph node metastasis, and advanced clinical stage in cervical cancer. In vitro study revealed that inhibition of miR-92a led to a significant reduction in the proliferation of HeLa cells via induction of cell cycle arrest at the G1 stage. In contrast, overexpression of miR-92a markedly promoted the proliferation of HeLa cells by promoting cell cycle progression. Further investigation revealed that miR-92a has a negative effect on protein levels, but not the mRNA levels, of p21 in HeLa cells, suggesting that p21 is a direct target of miR-92a. Overexpression of p21 eliminated the promoting effects of miR-92a on the proliferation and cell cycle progression of HeLa cells. However, knockdown of p21 reversed the suppressive effects of miR-92a downregulation on HeLa cell proliferation and cell cycle progression. Moreover, p21 was significantly downregulated in cervical cancer tissues compared to ANTs, suggesting that the increased expression of miR-92a may contribute to the decreased expression of p21, which further promotes cervical cancer growth. In conclusion, our study demonstrates that miR-92a promotes the proliferation of cervical cancer cells via inhibiting p21 expression and promoting cell cycle progression, highlighting the clinical significance of miR-92a in cervical cancer.
authors.affiliation: Department of Gynecology, Xiamen Maternal and Child Health Care HospitalXiamen, FujianP.R. China.
authors.forename: Zhiying
authors.initials: Z
authors.lastname: Su
authors.affiliation: Department of Obstetrics and Gynecology VIP, Xiamen Maternal and Child Health Care HospitalXiamen, FujianP.R. China.
authors.forename: Hua
authors.initials: H
authors.lastname: Yang
authors.affiliation: Department of Gynecology and Obstetrics, First Affiliated Hospital of Xiamen UniversityXiamen, FujianP.R. China.
authors.forename: Min
authors.initials: M
authors.lastname: Zhao
authors.affiliation: Department of Gynecology, Xiamen Maternal and Child Health Care HospitalXiamen, FujianP.R. China.
authors.forename: Yanlong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Gynecology, Xiamen Maternal and Child Health Care HospitalXiamen, FujianP.R. China.
authors.forename: Guoyi
authors.initials: G
authors.lastname: Deng
authors.affiliation: Department of Gynecology, Xiamen Maternal and Child Health Care HospitalXiamen, FujianP.R. China.
authors.forename: Ruixin
authors.initials: R
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D002453:Cell Cycle / Q000235:genetics*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D034622:RNA Interference; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D050759:Cyclin-Dependent Kinase Inhibitor p21; C541874:MIRN92 microRNA, human; D035683:MicroRNAs